Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jun 30;49(3):887–894. doi: 10.3892/ijo.2016.3593

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Maejima et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

The expression of PLXND1 and SEMA3E in human gastric carcinoma tissues. (A) PLXND1 and SEMA3E expression levels of cancerous and adjacent non-cancerous tissues from the gastric cancer patients were examined by qRT-PCR and normalized by the GAPDH expression level, and the ratios of cancer/non-cancer expression levels of PLXND1 and SEMA3E were evaluated. There were no significant differences in the PLXND1 expression ratios between the N0 and N+M+ patients (p=0.9171). The SEMA3E expression ratios in N+M+ patients was significantly higher than those in the N0 patients (p=0.0496). (B) The human gastric cancer tissues were classified according to the SEMA3E expression ratio into a high-SEMA3E group (cancer/non-cancer ≥1.5, n=15) and low-SEMA3E group (cancer/non-cancer <1.5, n=47). (C) In the intestinal type gastric cancer patients, the high-SEMA3E group (n=5) showed shorter survival than the low-SEMA3E (n=32) group (p=0.0017), while no significant relation was seen between the SEMA3E expression ratio and the overall survival in the diffuse type gastric cancer patients.